mice) had uncontrolled tumor growth and high mortality after ad5-traIl/Cpg administration. the ineffectiveness of ad5-traIl/Cpg therapy in the anti-PDCa1-treated and Batf3 −/− BalB/c mice was marked by an altered activation phenotype of the DC, as well as significantly reduced expression of type I IFn-stimulated genes and Il-15/Il-15r complex production. In addition, pDC-depleted and Batf3 −/− BalB/c mice had significantly decreased effector CD8 t cell infiltration in the primary tumor site compared with Wt mice after therapy. these data collectively suggest that pDC and CD8α DC carry out independent, but complementary, roles that are necessary to initiate an efficacious antitumor immune response after ad5-traIl/Cpg therapy. 
Introduction
Immune-based therapy for solid tumors provides the potential for long-lived protection against cancers of various stages-including metastatic cancer [1] . the development of successful cancer immunotherapeutic protocols depends on identifying the mechanisms that efficiently prime and activate effector cells within the immune system. One goal of many immunotherapeutic protocols is the generation of a systemic antitumor t cell response, which largely depends on the proper function of antigen presenting cells (aPC). Dendritic cells (DC) are the most potent aPC population that capture, process, and present tumor-derived ag to t cells via MHC I or II [2, 3] . When presented with tumor-derived ag in combination with co-stimulation and immunostimulatory cytokines, tumor-specific t cells differentiate into effectors that can directly kill tumor cells [2, 4, 5] . Because DC are essential for initiating antitumor t cell responses, understanding the roles played by specific DC subsets becomes paramount for optimizing immunotherapeutic protocols. Plasmacytoid DC (pDC) and CD8α DC are two DC subsets crucial in the generation of robust antitumor responses [4, 6] . pDC are recognized as the primary producers of type I interferon (IFn) after stimulation with various proteins or molecules containing pathogen-or damage-associated molecular patterns [6, 7] , while CD8α DC cross-present ag from exogenous sources (e.g., apoptotic tumor cells) in MHC I to CD8 t cells [8, 9] . the tumor necrosis factor (tnF) superfamily member tnF-related apoptosis-inducing ligand (traIl) is best known for its ability to selectively induce apoptosis in tumor cells [10, 11] . Moreover, systemically administered recombinant traIl protein and traIl death receptor-specific agonistic mab have been evaluated preclinically and in clinical trials for direct tumoricidal potential [12] . Our laboratory was the first to describe the utility of a recombinant replication-defective adenovirus encoding traIl (ad5-traIl) delivered locally into a tumor [13, 14] . When combined with immunostimulatory Cpg-containing oligodeoxynucleotides (Cpg), ad5-traIl induces a systemic antitumor t cell response in mice bearing localized subcutaneous renca tumors and in a mouse model of advanced renal cell carcinoma where an orthotopic primary renca tumor gives rise to lung metastases [15, 16] .
CD8 t cells are required for the complete eradication of the tumors in these models, suggesting the need for DC to cross-present tumor-derived ag. In addition, one expected function of the Cpg is to stimulate DC maturation for enhanced MHC/costimulatory molecule expression and inflammatory cytokine production. to address the specific necessity and function of pDC in the efficacy of the ad5-traIl/Cpg therapy, mice orthotopically challenged with renca tumors were depleted of pDC using a mab against PDCa1 [17] . We also examined the necessity and function of CD8α DC by examining the efficacy of ad5-traIl/Cpg immunotherapy in renca-bearing Batf3 −/− BalB/c mice [18] . We hypothesized that both pDC and CD8α DC would be required for the induction of antitumor immunity and the subsequent clearance of tumor. Data are presented to support this hypothesis, and the implications of these findings in regard to the development of current and future immunotherapeutic protocols are discussed.
Materials and methods

animals
Female wild-type BalB/c mice (7-8 wk old) and Batf3 −/− BalB/c breeder mice were purchased from the national Cancer Institute (Frederick, MD) and Jackson laboratories (Bar Harbor, Me), respectively. Batf3 −/− BalB/c mice were housed and bred under pathogen-free conditions at the aalaC-accredited University of Minnesota animal Care Facility. all animal procedures were approved by the University of Minnesota Institutional animal Care and Use Committee.
Cell lines the murine renal adenocarcinoma cell line, renca [19] was obtained from Dr. robert Wiltrout (national Cancer Institute, Frederick, MD). renca cells were maintained in rPMI supplemented with 10 % FBS, penicillin, streptomycin, sodium pyruvate, non-essential amino acids,
3
2-mercaptoethanol, and HePeS (a.k.a. complete rPMI) [15, 16] . renca-gle stably expresses firefly luciferase and green fluorescent protein (gFP) and was obtained from Dr. andrew Wilber (Southern Illinois University School of Medicine, Springfield, Il). renca-gle cells were maintained in complete rPMI supplemented with 0.3 μg/ml puromycin and 300 μg/ml zeosin. tumor challenge For intrarenal (Ir) tumor challenge, mice were anesthetized, a skin incision was made on the left flank, and 2 × 10 5 renca or renca-gle cells were injected through the intact peritoneum into the left kidney in a 100 μl volume of HBSS [16, 20] . pDC depletion was accomplished with two consecutive doses of anti-PDCa1 mab (clone 120g8 [21] ) at 500 μg/mouse [17] in 100-μl PBS i.p. on d 5 and 6 after tumor challenge. Mice treated with rat Igg1 anti-βgal mab (clone gl113) served as controls for pDC-depleted mice. On day 7, mice were reinjected in the same kidney with sterile PBS, ad5-traIl (10 9 pfu), and/or the nonmethylated Cpg ODn 1826 (5′-tccatgacgttcctgacgtt-3′, 100 μg; IDt, Coralville, Ia) in a 100 μl volume. renal and metastatic tumor burden were measured via bioluminescence imaging using a Xenogen IVIS Spectrum [16, 20] . renca-gle generated radiance (photons/s/cm 2 ) was calculated within a defined region of interest using living Image software (Version 2.5). For end time-point experiments, renal tumor burden was measured via weight (g) between d 18-21 when mice became moribund.
Flow cytometry
Spleens, tumor-bearing kidneys, and contralateral kidneys were harvested, homogenized into a single cell suspension via gentleMaCS Dissociator (Miltenyi Bioteck Inc., auburn, Ca), and then digested for 15-30 min in HBSS containing 0.56 Wuensch units/ml liberase Blendzyme 3 (roche, Branford, Ct) and 0.15 mg/ml Dnase I (Sigma, St. louis, MO). Cells were then blocked with anti-CD16/32 and normal mouse serum prior to staining with the following mab (eBioscience (San Diego, Ca) or Biolegend (San Diego, Ca)) and analyzed on a BD lSr II (BD Biosciences, San Diego, Ca) and FlowJo software (treeStar Inc., ashland, Or): DC-anti-CD11c-aPC/Cy7 or -Pe/Cy7, I-a d -PacBlue or -Pe, CD45r/B220-aPC/Cy7 or -PacBlue, CD317-aPC or -FItC, CD8-Pe-Cy7, CD40-Pe, CD86-Pe/Cy5, CD80-BV605; t cells-anti-CD3-PerCP/Cy5.5, CD4-Pe/Cy7, CD8-PacBlue, CD44-Pe or -aF700, KI-67-aF647, CD62l-Pe, CD45.2-Pe and -BV650. Intracellular staining for Foxp3 was done, as a dump gate, using a Foxp3 staining kit (eBioscience).
to specifically identify leukocytes within the tumorbearing kidney tissue or kidney vasculature, intravascular (i.v.) staining was done [22] . Briefly, mice were injected i. tumor-bearing kidneys were harvested 4 h after treatment and homogenized via gentleMaCS Dissociator. total rna was isolated using trIzol reagent (Invitrogen, Carlsbad, Ca), and 1 μg was reverse-transcribed using Superscript III. resulting cDna was used as a template for qPCr using taqMan primer/probe sets for Cxcl10, Ifit, Irf7, Isg15, Mda5, Mx1, and 18 s rrna (Pe applied Biosystems, Foster City, Ca).
Il-15/Il-15r complex quantitation by elISa tumor-bearing kidneys were harvested 24 h after treatment and homogenized in Cell extraction Buffer (Invitrogen, grand Island nY) supplemented with Complete Mini protease inhibitor (roche applied Science, Indianapolis, In) and 1 mM PMSF (Cell Signaling technologies, Danvers, Ma). Samples were incubated on ice for 30 min, spun at 3,000g at 4 °C for 10 min, and resulting supernatants were frozen at −80 °C until use. the amount of Il-15/Il-15r complex was determined via elISa (eBioscience).
Statistical analysis
Statistical analysis between groups was determined by oneway anOVa with a tukey's post hoc test or unpaired Student's t test, where appropriate. Statistical analyses of tumor growth kinetics and survival between groups were conducted via two-way anOVa and log-rank tests, respectively. Data were analyzed with Prism4 graphPad software, and statistical significance is indicated in figure legends [*** p < 0.0001; ** p < 0.001; * p < 0.05; not significant (n. s.)].
Results
DC-depleted mice succumb to tumor despite receiving ad5-traIl/Cpg therapy Different DC populations play synergistic and mutually exclusive roles during the initiation of an antitumor immune response [2, 17, 23, 24] . to determine the in vivo significance of pDC and CD8α DC in the efficacy of ad5-traIl/Cpg therapy in a model of advanced rCC, we treated Wt BalB/c mice with anti-PDCa1 mab (clone 120g8 [17] ), which depletes pDC, and utilized Batf3 −/− BalB/c mice, which are deficient in CD8α DC [18] . renca is derived from a spontaneously arising renal adenocarcinoma in BalB/c mice [25] and is widely used to model rCC. the H-2K/D d restriction of this model consequently limited us to using Batf3 −/− BalB/c mice: to our knowledge, there are no mice on the BalB/c background genetically engineered to be deficient in pDC. tumor-free Wt replete, anti-PDCa1-treated, and Batf3 −/− BalB/c mice showed normal development of splenic conventional DC (CD11c + MHC II + ) and CD8 + t cells, while having the expected reduction in frequency and number of pDC and CD8α DC (Fig. 1) . Both pDC-depleted mice and Batf3 −/− mice also showed normal development and maintenance of the converse DC subset, and we did not detect any major shifts in the major immune populations (i.e., t cells or B cells [26] [27] [28] ) shown to upregulate PDCa-1 (CD317) in certain settings in the anti-PDCa1-treated mice (data not shown), although smaller effects on such subsets cannot be completely excluded. the degree of pDC and CD8α DC depletion observed in tumor-free mice was also obtained in tumor-bearing mice (data not shown). the use of Batf3 −/− BalB/c mice proved to be superior to administering a depleting anti-CD8α mab, as mice given this mab had significant reductions in both CD8α DC and CD8 t cells. together, these mice and reagents gave us the ability to examine the therapeutic efficacy of ad5-traIl/Cpg in renca-bearing mice missing either pDC or CD8α DC, while maintaining an intact CD8 t cell compartment.
ad5-traIl/Cpg therapy induces a systemic antitumor t cell response in rCC-bearing mice capable of clearing local and metastatic tumors and prolonging survival [15, 16] . Use of ad5-traIl or Cpg individually can slightly decrease tumor burden, but only the ad5-traIl/Cpg combination significant reduces tumor burden and enhances survival [15, 16] . these data suggested that ad5-traIl-induced death creates the necessary tumor ag debris that is taken up by DC and presented to tumor-specific t cells, while Cpg serves to activate the DC for optimal ag presentation and t cell stimulation [15] . as our previous study did not specifically investigate the importance of pDC and CD8α DC in the ad5-traIl/Cpg-induced tumor eradication, we compared tumor outgrowth and survival of Wt replete, pDCdepleted, or Batf3 −/− BalB/c mice following treatment with PBS or ad5-traIl/Cpg therapy. (note-we did not treat mice with ad5-traIl or Cpg alone as they proved to be suboptimal therapy in our previous studies.) as before, Wt replete mice given ad5-traIl/Cpg displayed significantly suppressed tumor outgrowth, decreased frequency of mice with lung metastases, and prolonged survival compared with mice given PBS ( Fig. 2a-d ). In contrast, mice devoid of either pDC or CD8α DC displayed significant primary and metastatic tumor outgrowth and these groups had no survival benefit after ad5-traIl/Cpg therapy. together, these data demonstrate the necessity of both pDC and CD8α DC in the efficacy of ad5-traIl/Cpg therapy in this model of advanced rCC.
Phenotype of pDC and CD8α DC in Batf3
−/− and anti-PDCa1-treated mice following ad5-traIl/Cpg therapy given the lack of efficacy of ad5-traIl/Cpg therapy in the anti-PDCa1-treated and Batf3
−/− mice, we initially investigated the phenotype of pDC from Batf3 −/− BalB/c and CD8α DC from anti-PDCa1-treated mice after ad5-traIl/Cpg therapy. a number of reports have described the importance for pDC/CD8α DC cross talk during an immune response, suggesting that one DC subset can "license" another DC subset [5, 23, 24] . Most notably, pDC can specifically license myeloid DC and CD8α DC to process and present ag to CD8 t cells. With this in mind, we hypothesized that the absence of pDC would lead to decreased activation status in the CD8α DC compartment. However, there is little-to-no published data describing alterations in pDC activation as a result of a lack in CD8α DC. Splenocytes from tumor-bearing Wt replete, antiPDCa1-treated, and Batf3 −/− BalB/c mice were analyzed via flow cytometry 24 h after PBS or ad5-traIl/Cpg treatment to examine the activation status of the remaining endogenous DC populations. Interestingly, pDC from Batf3 −/− Balb/c mice exhibited a blunted activation phenotype 24 h after ad5-traIl/Cpg administration, as seen by significantly decreased CD40, CD80, and CD86 expression (Fig. 3a) . expression of these same proteins on CD8α −/− mice were run independently of the other groups, resulting in slight changes in the gating. b Mean (+SeM) frequency of DC and t cell populations. c Mean (+SeM) total number of DC and t cell populations. Cumulative data from two independent experiments, n = 3-4 mice/group/experiment. ns not significant, *p ≤ 0.05; ***p ≤ 0.01; ***p ≤ 0.001 using one-way anOVa with tukey's post hoc test DC in pDC-depleted mice was unchanged compared with Wt replete mice (Fig. 3b) . these results suggest that pDC maturation after ad5-traIl/Cpg therapy is dependent on cellular and/or soluble cues from CD8α DC, but the phenotypic maturation of CD8α DC does not require the presence of pDC. an early hallmark of both adenovirus type 5 (ad5) infection and Cpg stimulation is the induction of type I IFn cytokines, and both pDC and CD8α DC can make type I IFn after ad5 and Cpg stimulation [29] [30] [31] . Quantitation of type I IFn (be it IFnα or IFnβ) can be difficult from tissue or serum samples in some settings because the cytokines are quickly sequestered by the interferon αβ receptor (IFnar), reducing the amount a free cytokine below the level of detection of commonly used assays (such as elISa). to overcome this potential obstacle, we utilized quantitative real-time PCr (qPCr) to measure mrna expression of a panel of type I IFn-stimulated genes (Cxcl10, Ifit, Irf7, Isg15, Mda5, and Mx1) within the tumor-bearing kidney of Wt replete mice 4 h after injection of PBS, ad5-traIl, and/or Cpg. Mice treated with both ad5-traIl/Cpg had the greatest increase in cxcl10 and irf7 mrna expression compared with mice injected with PBS, ad5-traIl alone, or Cpg alone (Fig. 4a, b) . a similar trend was seen for ifit, isg15, mda5, and mx1 (data not shown). these results support our previous data demonstrating the superior therapeutic efficacy of ad5-traIl/Cpg over either component alone. We then examined the expression of the six type I IFn-stimulated genes in Wt replete, pDC-depleted, and Batf3 −/− BalB/c mice 4 h after PBS or ad5-traIl/Cpg injection. tumor-bearing Wt replete mice that received ad5-traIl/Cpg had substantial mrna upregulation of the six type I IFn-stimulated genes when normalized to tumor-free controls (Fig. 4c-h) . By comparison, ad5-traIl/Cpg-treated Batf3 −/− BalB/c mice had significantly reduced induction of mrna for these genes, and there was a decreased trend in mrna expression in similarly treated pDC-depleted mice. the data in Fig. 4 suggest alterations in the type I IFn response after ad5-traIl/Cpg injection contribute to the reduced efficacy of therapy. −/− BalB/c mice that received PBS or ad5-traIl/Cpg therapy. all test groups were compared with ad5-traIl/Cpg-treated Wt replete mice (cumulative data from three independent experiments; n = 3-5 mice/ group/experiment). *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 using oneway anOVa with tukey's post hoc test in a and two-way anOVa in b. log-rank tests were conducted in c, d
type I IFns can induce DC production of Il-15, and DC production of proinflammatory cytokines (including IFn) after Cpg stimulation is dependent on Il-15 [24, 32] . Further, the presence of endogenous or exogenous Il-15 during a tumor challenge promotes an antitumor CD8 t cell response capable of eradicating established tumors [33] . When we measured the amount of Il-15/Il-15r complex within tumor-bearing kidneys of Wt replete, anti-PDCa1-treated, and Batf3 −/− BalB/c mice after ad5-traIl/Cpg administration, we found a significant increase in the amount of Il-15/Il-15r complex within the kidneys of Wt replete mice over PBS-treated mice and when compared with anti-PDCa1-treated or Batf3 −/− BalB/c mice (Fig. 5) . Collectively, the data in Figs. 4 and 5 suggest both pDC and CD8α DC are required for the ad5-traIl/Cpginduced production of proinflammatory cytokines important for stimulating antitumor t cell responses. DC-depleted mice have a blunted CD8 t cell response after ad5-traIl/Cpg therapy pDC and CD8α DC have been implicated in the activation and expansion of tumor-specific CD8 t cells, and a CD8 t cell response is induced with ad5-traIl/Cpg therapy [15, 16] . the inability of ad5-traIl/Cpg therapy to control tumor outgrowth in pDC-and CD8α DC-deficient mice along with the decreased production of proinflammatory cytokines and DC maturation prompted us to evaluate CD8 t cell infiltration into tumor-bearing kidneys following therapy. as no renca-specific tumor ag have been identified to our knowledge, we determined the frequency of "effector phenotype" CD8 t cells (CD3 + CD8 + CD44 hi ) in the tumor-bearing kidneys of Wt replete, anti-PDCa1-treated, or Batf3 −/− BalB/c mice 5 days after receiving ad5-traIl/Cpg therapy. there was a significant increase in the frequency of CD3 +
CD8
+ CD44 hi cells in kidneys from ad5-traIl/Cpg-treated Wt replete tumor-bearing mice compared with PBS-treated mice when calculated from total live cells (Fig. 6a) or from total CD45.2 + leukocytes (Fig. 6b) . Similar increases in frequency in CD3
hi cells were not seen within the tumorbearing kidneys from ad5-traIl/Cpg-treated pDCdepleted or Batf3 −/− BalB/c mice. It is important to note that the CD8 t cell expansion seen in the Wt replete mice was not in response to adenovirus, as mice treated with ad5-traIl alone did not display this increase in CD8 t cell infiltration (data not shown). the diminished infiltration of CD8 t cells into the kidneys of tumor-bearing anti-PDCa1-treated mice after ad5-traIl/Cpg therapy was also not due to anti-PDCa1-mediated depletion of activated (IFn-stimulated) CD8 t cell (data not shown), as suggested by fact that this mab can deplete stromal cells and IFn-stimulated hematopoietic cells [26] . Our orthotopic rCC model is based on injection of renca cells into the kidney to form the primary tumor. Kidneys are highly vascular organs, making it likely that evaluation of leukocytes from tumor-bearing kidneys would include t cells "localized" within the kidney tissue and present in the kidney vasculature (i.e., in the circulating blood) at the time of organ harvest. thus, we used an intravascular staining technique [22] , in which Pe-conjugated anti-CD45. 
+ CD44 hi t cells were localized within the kidney tissue at the time of harvest-regardless of the experimental group (Fig. 6c, d ).
Subsequent analysis of the CD45.
hi t cells localized within the kidney at the time of harvest revealed a significant reduction in the frequency of Ki-67 + cells from ad5-traIl/Cpg-treated pDC-depleted or Batf3 −/− BalB/c mice (Fig. 6e) . CD11a is upregulated on ag-experienced CD8 t cells [34] and is also crucial for CD8 t cell-mediated killing of renca cells [35] . there was a significant reduction in CD11a expression on the tumorinfiltrating CD45.2
+ CD44 hi t cells from ad5-traIl/Cpg-treated pDC-depleted and Batf3 −/− BalB/c mice compared with Wt replete mice (Fig. 6f) . Collectively, these data demonstrate that the absence of pDC or CD8α DC results in the abrogation of the ad5-traIl/Cpg therapy-induced CD8 t cell immune response essential for the eradication of tumor cells in this model of advanced rCC.
Discussion
the ability to stimulate antitumor immunity is the primary goal of many active clinical trials [1] . the generation of t cell-mediated antitumor immunity should be (in theory) relatively straightforward, since a variety of ag expressed by tumors (including overexpressed tissue-differentiation ag, mutant proteins, and/or viral ag) can be recognized by the immune system. However, there are many aspects unique to t cells and other components of the immune system that inhibit optimal t cell activation. among the cells needed to generate antitumor t cell immunity, the importance of DC cannot be underemphasized. DC engulf fragments of dying tumor cells and process the numerous proteins into antigenic peptides for presentation via MHC I/II to t cells. a variety of methods can be employed to kill tumor cells in vivo (e.g., chemotherapy, radiation, or cryotherapy), but these methods frequently lack the specificity to safely and selectively target tumor cells and not harm normal, healthy cells. the immune system also has a wide arsenal of molecules that can induce cell death, some of which possess discrete tumoricidal activity. traIl and agonistic mab against traIl death receptors kill tumor cells, but have little-to-no toxicity to normal cells [36] . Our laboratory developed an immunotherapy that utilizes traIl-mediated tumor cell death in vivo that induces a robust systemic 5 renca cells and then treated with PBS or ad5-traIl/Cpg (rx) on day 7. tumor-bearing kidneys were harvested 24 h later, homogenized, and supernatants were analyzed in duplicate by elISa for Il-15/Il-15r complexes. n = 4 mice/group/experiment. *p ≤ 0.05; **p ≤ 0.01 using one-way anOVa with tukey's post hoc test Fig. 4 the absence of CD8α DC results in a decreased type I IFn signature within the tumor-bearing kidney after ad5-traIl/Cpg therapy. a, b Wt replete BalB/c mice were implanted Ir with 2 × 10 5 renca cells, treated with PBS, ad5-traIl alone, Cpg alone, or ad5-traIl/Cpg on day 7, and tumor-bearing kidneys were harvested 4 h later. total rna was isolated from tumor-bearing kidneys, reverse-transcribed into cDna, and analyzed by qPCr for the abundance of the type I IFn-stimulated genes cxcl10 and irf7. Mean fold change in type I IFn-stimulated genes was determined relative to tumor-free kidneys. c-h Wt replete, pDC-depleted, and Batf3 −/− BalB/c mice were implanted Ir with renca cells, treated with either PBS or ad5-traIl/Cpg (rx), and harvested as in a. Mean fold change in type I IFn-stimulated genes was determined relative to tumor-free kidneys. Data are representative of three independent experiments, n = 3-5 mice/group/experiment. ns not significant, *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 using one-way anOVa with tukey's post hoc test antitumor immune response mediated by tumor-specific CD8 t cells [13, 15, 16] . to further understand the mechanism by which this immunotherapeutic approach is successful, we performed a series of experiments that demonstrated the importance of two distinct DC populations, pDC and CD8α, in the generation of the antitumor CD8 t cell response.
the development of immunotherapies that specifically use or target DC is a major area of interest in the treatment of cancer [37] . While the potential for DC-mediated tumoricidal activity has been reported [38] [39] [40] , the intended role of DC in tumor immunotherapy is to generate an antitumor t cell response with the potential to deal with disseminated and/or recurrent disease. While the data presented suggest the key role of pDC and CD8α DC in the success of ad5-traIl/Cpg therapy in a model of advanced rCC, it is also important to note that the roles played by these DC populations are partially dependent on the successful induction of traIl-mediated apoptotic tumor cell death. It is reasonable to think that any agent that 
CD44
hi effector phenotype CD8 t cells. Cumulative data from two independent experiments shown, n = 5 mice/group/experiment. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 using one-way anOVa with tukey's post hoc test induces tumor cell apoptosis would achieve similar effects, but there are many factors that can influence whether apoptotic cell death leads to an immunogenic or tolerogenic outcome [41] . traIl is unique in the sense that it selectively induces apoptosis in tumor cells [10] , but there is still much to learn in regard to how tumor cells killed by traIl are perceived by DC and other cells of the immune system. We focused our investigation to pDC and CD8α DC, as these DC subsets are classically defined by being able to respond to Cpg (and producing proinflammatory cytokines) and cross-present tumor ag from the apoptotic tumor cells. the Cpg ODn used in our studies is thought to function as an adjuvant to activate the immune system to more efficiently respond to the tumor [42] . Unmethylated Cpg-containing motifs are specifically recognized by tlr9, and murine pDC, Mφ, B cells, and all myeloid DC subsets identified to date express tlr9 and respond to Cpg [43, 44] . thus, the inability of pDC-depleted mice to eliminate tumor after ad5-traIl/Cpg therapy cannot be explained simply by a failure to respond to Cpg. tlr-activated pDC have increased MHC and costimulatory molecule expression giving them the ability to stimulate t cells [45] . activated pDC also undergo a differentiation process that features production of proinflammatory cytokines and other molecules that act on other cells of the immune system. In our hands, anti-PDCa1-treated tumor-bearing mice had reduced proinflammatory cytokine production (based on IFn-stimulated gene expression and Il-15/Il-15r production) and effector CD8 t cell infiltration into the tumorbearing kidney after ad5-traIl/Cpg therapy compared with Wt replete mice, which together likely contributed to the increased tumor growth and decreased survival.
In vivo depletion of CD8α DC can be achieved a number of ways. For us Batf3 −/− BalB/c mice proved to be ideal, as these mice are devoid of CD8α DC while still having CD8 t cells [18] . Batf3 encodes a transcription factor highly expressed in conventional CD11c + DC, and splenic CD11c + conventional DC from Batf3 −/− mice lack the ability to cross-present ag to CD8 t cells [18] . thus, the lack of significant effector CD8 t cell infiltration into the tumorbearing kidneys of Batf3 −/− BalB/c mice and absence of a therapeutic benefit after ad5-traIl/Cpg administration were expected. It was unexpected to see, however, the minimal response by the Batf3 −/− BalB/c mice in regard to IFn-responsive gene expression and Il-15/Il-15r production after ad5-traIl/Cpg therapy-especially since the Batf3 −/− BalB/c mice still have pDC (Fig. 1) . In addition, there was minimal upregulation of costimulatory molecules on the pDC from Batf3 −/− BalB/c mice after ad5-traIl/Cpg therapy. these data suggest that of the two DC populations investigated, CD8α DC may play a more important role in the successful treatment of advanced rCC with ad5-traIl/Cpg than pDC.
there is increasing evidence, suggesting the necessity for DC subset interaction for the development of optimal t cell responses. lou et al. [23] showed that a mixture of Cpg-stimulated pDC plus CD11c hi
CD11b
+ B220 − myeloid DC synergized to induce increased ag-specific CD8 t cell responses and antitumor immunity compared with either DC subset alone. Similarly, Kuwajima et al. [24] found pDC were required for the production of Il-12 by Cpg-stimulated conventional DC. the role for pDC being essential to license CD8α DC function has been shown in multiple models [23, 46] , and data presented herein suggests the possibility for pDC/CD8α DC cross talk is important in the success of ad5-traIl/Cpg immunotherapy. Both cell-to-cell contact and soluble factors have been suggested to be the molecular mechanism behind DC subset communication [5, 23, 24, 46, 47] , but our experiments were not designed to define which of these previously defined (or perhaps some other) mechanisms were being used by the pDC and CD8α DC to communicate with one another, as this would have significantly broadened the scope of the study beyond its initial intention. Future studies are planned to specifically address this aspect, as it will be important to understand the signaling methods that allow pDC and CD8α DC to talk with one another for the generation of a successful antitumor immune response after ad5-traIl/Cpg therapy and apply this knowledge to scenarios where the therapy is ineffective.
For years (and still today), metastatic or unresectable cancers of many types have been treated by systemic administration of a drug that directly or indirectly (via modification of the tumor microenvironment) leads to tumor cell death. this approach required careful dosing to demonstrate a reduction in tumor growth without inducing toxic side effects. the refinement of powerful imaging and minimally invasive techniques has improved the identification and access to tumors in situ as well as increasing the types of therapies that can be performed to treat cancer in patients that may have previously had limited therapeutic options [48] . thus, it seems logical to envision a setting where cancer immunotherapies designed to activate DC would benefit from local injection of the therapeutic molecules directly into the tumor microenvironment. a number of Cpg oligonucleotides have been tested in clinical trials, mostly in combination with tumor vaccines and given subcutaneously (perhaps for convenience), and have shown evidence of antitumor activity [49] . However, it is not unreasonable to consider a protocol consisting of Cpg delivered directly into the tumor-alone or in combination with another drug with tumoricidal activity. For example, we have examined the tolerability of direct intratumoral injection of ad5-traIl in a phase I clinical trial in men with locally confined prostate cancer [50] , or the systemic administration of traIl death receptor agonists [51] , which could easily be combined with local Cpg therapy. Other drug regimens are feasible, but the potential benefit of intralesional administration of cancer therapies, like Cpg, in human remains to be determined. the findings presented herein are important to the basic biological understanding of how ad5-traIl/Cpg therapy for cancer works, as well as being essential for understanding how to modify the use of ad5-traIl/Cpg when immunomodulatory co-morbidities are present. For example, renca-bearing diet-induced obese (DIO) mice do not respond to ad5-traIl/Cpg therapy and ultimately succumb to tumor burden, unlike lean controls [20] . I-a d+
CD11c
hi CD11b + splenic DC from the DIO mice had decreased t cell stimulatory capacity compared with the same population of cells from lean mice. However, these markers identify a unique "immunosuppressive" DC population [20] that is mutually exclusive from pDC and CD8α DC (based on the markers used in this study). It is tempting to speculate that in addition to the immunosuppressive I-a d+
hi CD11b + DC in DIO mice, altered function of pDC and/or CD8α DC (be it cytokine production, ag uptake/processing/presentation, or communication needed for DC licensing) also contribute to the failure of ad5-traIl/Cpg therapy in tumor-bearing obese mice. regardless of the different DC populations (pDC, CD8α DC, or immunosuppressive CD11b + DC) examined, knowing which specific DC populations and their functional characteristics are essential for the success of ad5-traIl/Cpg therapy.
